Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (referred to in metadata as Skye Bioscience, Inc.) on August 19, 2015. The company is a Nevada corporation focused on proprietary cannabinoid-based therapeutics. The report details a material definitive agreement entered into on August 19, 2015, regarding a private placement financing.
Key Financial Metrics and Transaction Details
- Financing Proceeds: The company agreed to raise an aggregate of $5,000,000.
- Securities Issued: 5,000 shares of Series B Preferred Stock and warrants to purchase 6,250,000 shares of common stock.
- Purchase Price: $1,000 per Preferred Share (including related warrants).
- Warrant Terms: Exercise price of $1.15 per share with a five-year term.
- Preferred Stock Conversion: Convertible into common stock at a price of $0.80 per share.
- Placement Agent Compensation: Midtown Partners & Co., LLC will receive $213,000 in cash and warrants to purchase 187,500 shares of common stock at $1.15 per share.
- Use of Proceeds: Funding advancement of proprietary cannabinoid-based therapeutics and general corporate purposes.
Material Changes and Agreements
The primary material change is the entry into a Securities Purchase Agreement and a Registration Rights Agreement. Under the Registration Rights Agreement, the company must file a registration statement within 30 calendar days of closing to register for resale 130% of the common stock underlying the Preferred Shares and all common stock underlying the Warrants.
If the registration statement does not become effective within specified timeframes, the company is obligated to pay the purchasers a penalty of 2.0% of the aggregate purchase price per month until the registration becomes effective or the shares can be sold under Rule 144 without restrictions.
Preferred Stock Provisions
- Anti-Dilution: Includes customary anti-dilution protection.
- Force Conversion: The company may force conversion if the VWAP exceeds 200% of the conversion price ($0.80) for 20 trading days and daily volume exceeds 200,000 shares.
- Designation: Created via Certificate of Designation filed with the Nevada Secretary of State.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue forecasts, or profit margins. The outlook is tied to the successful closing of the financing, expected no later than August 21, 2015, subject to customary conditions.
Risks and Contingencies:
- Registration Risk: Failure to timely file or have the registration statement declared effective triggers monthly cash penalties (2% of purchase price).
- Dilution: The issuance of preferred stock and warrants, along with the 130% registration overhang, represents significant potential dilution to existing common shareholders.
- Market Conditions: The force conversion right is contingent on specific market volume and price thresholds being met.
Investor Verification Checklist
- Verify the actual closing date of the financing (expected by August 21, 2015) and confirmation of fund receipt.
- Confirm the filing of the registration statement within the required 30-day window to avoid penalty payments.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific anti-dilution formulas and liquidation preferences.
- Assess the impact of the 130% registration overhang on future share liquidity and price.
- Monitor the company's cash burn rate relative to the $5 million raised to determine runway for therapeutic development.